A Study To Test The Effect Of Apatinib On P450 Enzymes
Status:
Unknown status
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2（VEGFR-2）,
inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with
advanced cancer evaluated the effect of Apatinib on CYP450 function by comparing the
pharmacokinetics of CYP-specific probe drugs in the presence and absence of Apatinib. The
probes used included Nifedipine (CYP3A specific), warfarin (CYP2C9 specific).